Crizonix is the global first generic preparation of Crizotinib.
Crizonix – A Project of Reinforcelab
Crizonix is the global first generic preparation of Crizotinib. CRIZONIX is indicated as the first-line treatment of adults with ALK-positive advanced Non Small Cell Lung Cancer(NSCLC) and ROS1 (+) NSCLC. Crizotinib is an ALK and ROS1 (c-ros oncogene 1, receptor tyrosine kinase) inhibitor. This Crizonix is 13 times affordable than originator and the quality of the product is to that of International Standard GMP compliant. Beacon Pharmaceuticals Limited manufactured this product in a dedicated oncology facility. They are providing worldwide delivery support.
During this project we have completely changed the layout and place the menu in the side bar. At the same time, we have ensured best quality design for the website to make it user friendly for the customers.  Also, set several call action to increase the sales rate of the product’s website.
Sofosvel is the global first generic oral tablet for pan-genotypic Chronic Hepatitis C treatment manufactured by Beacon Pharmaceuticals Limited.
Project Description
Sofosvel is the global first generic oral tablet for pan-genotypic Chronic Hepatitis C treatment manufactured by Beacon Pharmaceuticals Limited. This combination (Sofosbuvir 400 mg + Valpatasvir 100 mg) drug has been approved by US FDA & European Commission for treatment of patients with all genotypic Chronic Hepatitis C virus infection. Sofosvel is used without cirrhosis or with compensated cirrhosis, and patients with advanced cirrhosis (Decompensated).
We have ensured best quality design for the website to make it user friendly for the customers. We have also set several call action to increase the sales rate of the product’s website.
Tagrix (Osimertinib) is a product website which is a blockbuster product of Beacon Pharmaceuticals Limited.
Project Description
Tagrix (Osimertinib) is a product website which is a blockbuster product of Beacon Pharmaceuticals Limited.  the first of its kind to be indicated for patients with T790M mutation-positive NSCLC, irrespective of previous treatment with an EGFR tyrosine kinase inhibitor (TKI). Tagrix (Osimertinib) targets both the EGFR mutation that triggers cancer development and T790M. Tagrix is the first global generic preparation of Tagrix (Osimertinib) which is approved by Directorate of Drug Administration, Ministry of Health and Family Welfare, People’s Republic of Bangladesh.
Project Feature
We have ensured best quality design for the Tagrix website to make it user friendly for the customers . We have also set call action to increase the sales rate of the product. We also tried to make the full quality product’s website with an affordable price.
Beacon Pharmaceuticals Limited a Project of Reinforce Lab
Beacon Pharmaceuticals Limited is the number one oncology pharmaceutical companies of Bangladesh. Also one of the leading and fastest growing pharmaceutical companies of Bangladesh. The Company started its operation in 2006.
Beacon Pharmaceuticals Limited is the number one oncology pharmaceutical companies of Bangladesh. Also one of the leading and fastest growing pharmaceutical companies of Bangladesh. The Company started its operation in 2006.
Manufacturing plant of Beacon has the finest infrastructure & facilities developed and engineered by European consultants to conform world class standards like US FDA,UK MHRA, TGA Australia and WHO GMP. Beacon has dedicated facilities to manufacture lifesaving oncology, Biotech and Hi-Tech & conventional general products. The company manufactures more than 200 world class generic drugs and even successfully introduced a number global first generic drug.
